{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Media companies are feeling their own pain from the COX-2 debacle. Now that Pfizer has suspended its multimillion-dollar consumer advertising program for its COX-2 inhibitor painkiller, Celebrex, and Merck has taken its similar -- and similarly advertised -- drug, Vioxx, off the market, the prescription drug ad market is not looking nearly as healthy as it seemed earlier this year.", "headline": {"main": "Madison Ave. Sharing Drug Makers' Pain", "kicker": "THE MEDIA BUSINESS: ADVERTISING"}, "abstract": "Prescription drug ad market is not looking nearly as healthy as it seemed earlier in year now that Pfizer Inc has suspended its multi-million-dollar consumer advertising campaign for arthritis drug Celebrex and Merck & Co has taken its similar--and similarly advertised--drug Vioxx off market; Pfizer spent $87.6 million in major media spending on Celebrex ads last year and was on its way to surpassing that this year; Merck's decision in late September to withdraw Vioxx brought abrupt end to direct-to-consumer ad spending that had run to $78 million last year; graph (M)", "print_page": "1", "word_count": 795, "_id": "4fd257118eb7c8105d800caa", "snippet": "With the suspension of the consumer advertising program for Celebrex, the prescription drug ad market is not looking as healthy as it seemed earlier this year.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/21/business/media/21adco.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "ADVERTISING (TIMES COLUMN)"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "ADVERTISING"}, {"name": "subject", "value": "MARKETING AND MERCHANDISING"}, {"name": "subject", "value": "ADVERTISING AND MARKETING"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Nat", "rank": 1, "lastname": "IVES"}], "original": "By NAT IVES"}, "document_type": "article", "pub_date": "2004-12-21T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In the mid-1990's, the medical community reached an inescapable conclusion. Researchers at the Stanford University Medical School and elsewhere who had long been monitoring arthritis and rheumatism patient records had found that thousands of patients, perhaps as many as 16,500, were dying annually from bleeding ulcers and other problems caused by widely used painkillers like ibuprofen. Within a few years, a new class of pain relievers, the so-called COX-2 inhibitors, burst onto the market with the promise they might reduce that toll. Sales of the best known products, Celebrex and Vioxx, quickly skyrocketed -- thanks in part to changes in federal rules in 1997 that made it much easier for drug makers to advertise medications directly to consumers on television, in newspapers and in magazines.", "headline": {"main": "Medicine Fueled by Marketing Intensified Trouble for Pain Pills"}, "abstract": "Story of COX-2 drugs, class that includes Merck's Vioxx and Pfizer's Celebrex and Bextra, is part of age-old search for safer pain treatments, and illustrates how confluence of medicine and marketing can dash hopes; also shows how difficult it is for FDA to to monitor safety of drugs after they have been approved for market; since drugs' release, companies have spent millions on advertising to public and marketing and promoting to doctors, with result that many medical experts say Celebrex and Vioxx have been too widely prescribed to patients who could get same same relief from cheaper, over-the-counter drugs; Pfizer and Merck have defended marketing as accurate and responsible and consistent with regulation, but some researchers say rapid rise of class of drugs is emblematic of drug companies' efforts to spur use of costly new medicines; recently released results of trial by National Cancer Institute, showing risks of hearts attacks in patients using Celebrex, sent drug stocks plummeting and cast grave doubts on future of entire COX-2 category; details of study noted; graph shows how COX-2 drugs have contributed to companies' bottom lines; photo (L)", "print_page": "1", "word_count": 2411, "_id": "4fd2414d8eb7c8105d7d9955", "snippet": "The story of COX-2 drugs is an example of how difficult it is for the F.D.A. to monitor the safety of drugs after they have been approved for the market.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/19/business/19drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "organizations", "value": "PFIZER INCORPORATED"}, {"name": "organizations", "value": "NATIONAL CANCER INSTITUTE"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "ADVERTISING AND MARKETING"}, {"name": "subject", "value": "BEXTRA (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "COX-2 INHIBITORS (DRUGS)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1}, {"organization": "", "role": "reported", "firstname": "Gina", "rank": 2, "lastname": "Kolata"}, {"organization": "", "role": "reported", "firstname": "Andrew", "rank": 3, "lastname": "Pollack"}, {"organization": "", "role": "reported", "rank": 4}], "original": "This article was reported by Barry Meier, Gina Kolata and Andrew Pollack and written by Mr. Meier.; Stuart Elliott contributed reporting for this article"}, "document_type": "article", "pub_date": "2004-12-19T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 2, "offset": 0, "time": 49}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}